SOT RSESS-GSLC Webinar: Industry Perspective on Regulatory Toxicology

Slides:



Advertisements
Similar presentations
UPDATES TO THE OSHA HAZARD COMMUNICATION STANDARD Safety Data Sheets (SDS), Labels, & Pictograms.
Advertisements

CONFERENCE ON “ FOOD ADDITIVES : SAFETY IN USE AND CONSUMER CONCERNS“ JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY NAIROBI, 24 JUNE 2014.
Dietary Supplements Public Meeting November 15, 2004 George A. Burdock, Ph.D. Diplomate, American Board of Toxicology Fellow, American.
© 2011 Underwriters Laboratories Inc. Product Recall and the Supply Chain: ISO Best Practices Robert Pollock Chair, US Technical Advisory Group for ISO.
MFRPS Lesson Learned North Carolina
Why Are We Here? The History and Landscape of DTC Genetic Tests Elizabeth Mansfield, Ph.D. OIVD/CDRH/FDA March 8, 2011 Molecular and Clinical Genetics.
INFLUENCE OF CONSUMER PERCEPTION ON NEW FOOD PRODUCT DEVELOPMENT.
1 Promoting Safe Medicine With Track and Trace Systems SRC Technologies, Inc.
What Do Toxicologists Do?
International Regulatory Capacity Building Global Curriculum Project.
1 Webinar on: Establishing a Fully Integrated National Food Safety System with Strengthened Inspection, Laboratory and Response Capacity Sponsored by Partnership.
DSHEA and Bioavailability Elizabeth A. Yetley, Ph.D. Ctr. Food Safety & Applied Nutrition Food and Drug Administration.
Pharma & Healthcare Logistics Development Roadmap for Luxembourg T h e r e i s s o m e t h i n g g o i n g o n i n L u x e m b o u r g ! T A S T r u s.
1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
Globally Harmonized System of Classification and Labeling (GHS)
Best Practice in Attracting and Retaining Talent from the International Nuclear Industry.
Ashland Specialty Ingredients IFAC’s cGMP Audit Guide How the Food Ingredient Industry has Responded to FSMA and Food Safety Audits Priscilla Zawislak.
New Zealand Medicines and Medical Devices Safety Authority A business unit of the Ministry of Health.
1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.
Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
INTRODUCTION TO RA.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
1 Update on Nanotechnology Activities in CDER and FDA Keith O. Webber, Ph.D. Deputy Director OPS/CDER/FDA ACPS Meeting Tuesday, July 22, 2008.
Food Safety Assurance August Scope of food quality & food safety The term “food” covers any unprocessed, semi- processed, or processed item that.
Ensuring Food Safety in Europe through Scientific Cooperation and Networking The Role of EFSA Carola Sondermann EFSA Polish Focal Point – Annual Experts.
Dietary Supplements. Definition by DSHEA Product that is to supplement a healthy diet. Includes ingredients such as vitamins, minerals, herbs, botanicals,
Working together with EFSA in making Europe’s food safe Warszawa, 16. April 2013 Cooperation between EFSA and Member States Jacek Postupolski National.
The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.
Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.
“We work to prevent and are prepared to respond to threats to our health and safety through coordinated efforts across the country and around the world.”
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
Proposed Regulations for Foreign Supplier Verification Programs (FSVPs)
Chemistry making a world of difference Responsible Care ® - Thrusts in Europe Dr Richard Robson Cefic Director APRCC, Manila, Philippines 17 th November.
Council for Responsible Nutrition FDA Public Meeting on New Dietary Ingredients Annette Dickinson, Ph.D. November 15, 2004.
Towards an Industry Advisory Group An Open Round-Table Conversation 19 May 2009 Do not copy or reproduce without express written permission of Foresight.
DIETARY SUPPLEMENTS Dietary supplements are products that can be added to people’s diets. They include vitamins, minerals, herbs, and amino acids.
Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.
Compliance Promotion Formalizing an Approach to Support Stakeholder Compliance.
Agenda for Session Compliance in Clinical Research
1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
Medical Device Regulations in Canada; Key Challenges and International Initiatives.
The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.
Center for Food Safety and Applied Nutrition Systems Recognition Import System Public Meeting March 21, 2016 Caroline Smith DeWaal International Food Safety.
BIS 375 MASTER Leading through innovation/bis375masterdotcom.
CJA 234 MART The power of possibility/cja234martdotcom BIS 375 Entire Course FOR MORE CLASSES VISIT BIS 375 Week 1 Discussion Question.
Brought to you by: GMP Inspection Lessons Early results from the first few years of inspections have highlighted some common violations of the GMP regulation.
ดูแลด้วยความรับผิดชอบ
Mutagenic Impurities: Guidances Update w/ CMC Perspectives
Copyright © 2016 by Mosby, an imprint of Elsevier Inc.
The Information Professional’s Role in Product Safety
Karen Proud, President Consumer Health Products Canada
Regulatory Toxicology & Risk Assessment in Consulting
Dietary Supplements: What you should know
Over the Counter (OTC) Drugs & Dietary Supplements Market Global Opportunity Analysis and Industry Forecast,
Worksafe BC.
BIS 375 Education for Service-- tutorialrank.com
Communication and Consultation with Interested Parties by the RB
Beyond Academia.
Lockheed Martin Canada’s SMB Mentoring Program
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
AERODROME CERTIFICATION COURSE
Response Teams – Planning and Preparation
Micro-Learning: Risks, Rewards & Alternatives
Dr Manisha Shridhar Regional Advisor WHO-SEARO
Briefing by Department of Health to joint meeting of the Portfolio Committees on Agriculture, Forestry and Fisheries, Health, Trade and Industry, Rural.
Introduction of the new Canada Consumer Product Safety Act
Presentation transcript:

SOT RSESS-GSLC Webinar: Industry Perspective on Regulatory Toxicology Amy L. Roe, PhD, DABT Global Product Stewardship The Procter & Gamble Company 31 October 2017

What does regulatory toxicology mean to industry? Just 1 part of the overall safety assessment Objective Safety Regulatory Toxicology External Perception Regulatory Toxicology requirements/guidance should be considered MINIMUM requirements For some ingredients, company may be more conservative in their internal risk assessments Company may have specific ingredients they choose to avoid even though regulations allow (e.g. BPA) Company may have consumer habits and practices data that weigh in to the safety assessment

What does regulatory toxicology mean to industry? Regulatory path and requirements based on product claim (drug versus dietary supplement versus food) – any inherent toxicity will still be the same regardless the regulatory path

What does regulatory toxicology mean to industry? In addition to major government agencies (e.g. EPA, FDA, Health Canada, EMA, etc), may include requirements from: Country-specific Boards of Health, state-specific requirements (California Proposition 65), pharmacopeias (e.g. USP) Requires close partnership with internal regulatory manager and others as needed (e.g. QA, analytical, process and formulation, legal, etc.) One of the most interesting and sometimes challenging aspects occur when we differ in interpretation of regulations across industry, government, and legal (NOTE: to illustrate this point, I’ll briefly talk through the example of pesticide levels in botanical raw materials for use in dietary supplements versus drug product or food, DSHEA vs drug regulations)

“Hot Topics” in regulatory toxicology (personal healthcare industry perspective) FDA Monograph Reform New opportunities for product innovations May require additional work for some drug actives ICH Elemental Impurities Ever-increasing analytical detection limits often translate into new regulations and challenges for ingredients that have a long history of safe use May require reformulation which can completely change aspects of product (e.g. degradant profile, stability issues) New Dietary Ingredient Regulations

A “typical” day in industry Based on experiences in both Pharma (Rx) and Over-the-Counter/Supplement space Pharma timelines are considerably longer; planning regulatory strategies across years (10-12) which makes day-to-day somewhat more predictable OTC and supplement product timelines are much shorter (months to 2-3 years) coupled with hundreds of SKUs in the global marketplace New regulatory requirements can impact a large number of products Changes to a formulation may completely change product profile (e.g. stability, degradants, etc.)

A “typical” day in industry Unpredictable issues can arise that may result in products considered mislabeled, misbranded, or adulterated Product may get shipped or wharehoused incorrectly which can alter formulation (e.g. precipitation of drug actives) We’re human – mistakes may get incorporated into product labels (dosing instructions, cautionary statements, etc). Principle-led companies find and correct these mistakes immediately Manufacturing mistakes (Quality Incidents/Serious Quality Incidents) Consumer complaints (safety surveillance) need to be addressed New studies/findings reported in the literature may have implications for product or product ingredients (sometimes these studies are picked up by media and intensify scrutiny) Social media – must respond to overt misuses of products

Entry-level responsibilities and growth opportunities Internal and external training available, often specific to assigned product category Assigned a daily coach (business-specific) and a mentor (company-wide) Important to partner closely with regulatory counterpart and others (QA, analytical, legal, etc.); especially when issues arise Initially, interfaces with regulatory agencies may be limited, or you will shadow a more experienced toxicologist Growth opportunities may include serving on trade association task forces (e.g. Consumer Health Products Association), other organizations like USP Expert Committees, more advanced positions may include government advisory panels

Graduate student/Post-doc preparation advice Solid technical foundation is #1! (we are all scientists first and foremost) Begin to think about where your research fits within the appropriate regulatory agency (EPA, FDA, etc.) What other regulations or authorities might apply to your work? (e.g. CA Prop 65, USP) When preparing for an interview with a certain agency or company – know something about the history and authority of the regulatory agencies most applicable to the job, have some general knowledge of the most important guidances that govern that business

Regulators and Industry have the same ultimate goal To protect consumers by ensuring safe products are in the marketplace Thank You!